Last updated: May 29, 2026

Application No. 17/928,427

Methods and Treatment Involving Antibodies to IL-18

Final Rejection

Filed

Nov 29, 2022

Priority

Jun 01, 2020 — provisional 63/032,929 +1 more

Examiner

LANDSMAN, ROBERT S

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Avalo, Inc.

OA Round

2 (Final)

Interview Optional

— +12.9% interview lift. Interview lift (+12.9%) is below the 15.0% threshold. A written response is recommended.

Based on 1254 resolved cases, 2023–2026

Examiner Intelligence

LANDSMAN, ROBERT S View full profile →

Grants 81% — above average

Career Allowance Rate

1020 granted / 1254 resolved

+21.3% vs TC avg

Moderate +13% lift

Without

With

+12.9%

Interview Lift

resolved cases with interview

Fast prosecutor

2y 1m

Avg Prosecution

42 currently pending

Career history

1287

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

23.8%

-16.2% vs TC avg

§102

11.0%

-29.0% vs TC avg

§112

27.0%

-13.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1254 resolved cases

Prosecution Timeline

Nov 29, 2022

Application Filed

Nov 04, 2025

Non-Final Rejection mailed

Mar 03, 2026

Response Filed

Apr 22, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/006,169

Patent 12637508

COMPOUNDS AND METHODS TARGETING HUMAN AND MOUSE INSL5

3y 4m to grant Granted May 26, 2026

18/844,732

Patent 12637513

METHOD OF TREATING CANCER BY ADMINISTERING AN INHIBITOR OF ERYTHROPOIETIN RECEPTOR ACTIVITY COMPRISING EITHER ERYTHROPOIETIN RECEPTOR OR ERYTHROPOIETIN PROTEIN

1y 8m to grant Granted May 26, 2026

18/844,737

Patent 12637514

EPO RECEPTOR AGONISTS AND ANTAGONISTS

1y 8m to grant Granted May 26, 2026

17/794,582

Patent 12624112

ANTI-ST2 ANTIBODY AND APPLICATION THEREOF

3y 9m to grant Granted May 12, 2026

18/523,048

Patent 12624114

METHOD OF REDUCING SERUM AMYLOID A (SAA) PROTEIN LEVELS IN A PATIENT BY ADMINISTERING AN INTERLEUKIN-33 (IL-33) ANTIBODY

2y 5m to grant Granted May 12, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

81%

Grant Probability

94%

With Interview (+12.9%)

2y 1m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1254 resolved cases by this examiner. Grant probability derived from career allowance rate.